The crystal structure of the human immunodeficiency virus type 1 (HIV-1) neutralizing, murine Fab 83.1 in complex with an HIV-1 gp120 V3 peptide has been determined to 2.57 Å resolution. The conformation of the V3 loop peptide in complex with Fab 83.1 is very similar to V3 conformations seen previously with two other neutralizing Fabs, 50.1 and 59.1. The repeated identification of this same V3 conformation in complex with three very different, neutralizing antibodies indicates that it is a highly preferred structure for V3 loops on some strains of the HIV-1 virus.
Introduction
The human immunodeficiency virus type 1 (HIV-1) virus is a membrane-coated lentivirus whose outer surface is embedded with spikes made up of the envelope glycoproteins gp120 and gp41. These two surface proteins are originally encoded by the single polypeptide chain gp160 and, after proteolytic cleavage (McCune et al., 1988) , stay noncovalently associated on the viral surface as oligomeric, probably trimeric, assemblies (Earl et al., 1990; Gelderblom et al., 1987; Ozel et al., 1988; Pinter et al., 1989; Weiss, et al., 1990) . The gp41 protein contains a membrane-spanning domain that anchors it to the viral membrane so that gp120 remains noncovalently associated around the membranebound trimeric gp41. The gp120 protein is responsible for binding to the major cellular receptor, CD4 (Dalgleish et al., 1984; Klatzmann et al., 1984) , as well as to coreceptors, such as CCR5 (Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996) or CXCR4 .
Sequence analysis of gp120 has revealed five variable regions in the protein, termed V1-V5 (Starcich et al., 1986) . The third hypervariable region (V3) of gp120 consists of approximately 40 residues (varying in length depending on the viral isolate) with a conserved disulfide bridge (Cys 296 -Cys 331; HXB2 numbering) at the base of the loop. The V3 loop region is integral to many aspects of HIV-1 viral infectivity. Variation in the V3 sequence is linked with changes in cell tropism (Cann et al., 1992; Chavda et al., 1994; Chesebro et al., 1992 Chesebro et al., , 1996 Harrowe and ChengMayer, 1995; Hwang et al., 1991; Mammano et al., 1995; Stamatatos and Cheng-Mayer, 1993) , the ability to induce syncitia (Bhattacharyya et al., 1996; de Jong et al., 1992b; Fouchier et al., 1992; Hogervorst et al., 1995; Milich et al., 1997) , the ability to be neutralized by soluble CD4 (Hwang et al., 1992) , and the progression from initial infection to full-blown AIDS (Distler et al., 1995) . These features of V3 can all be correlated with its role in the interaction of gp120 with coreceptors CCR5 or CXCR4 (Cocchi et al., 1996; Speck et al., 1997; Wang et al., 1998; Xiao et al., 1998) . The V3 loop has also been termed the "principal neutralizing determinant" (Javaherian et al., 1989) because peptides and protein fragments containing the V3 region were originally described as having a high propensity to elicit neutralizing antibodies (Goudsmit et al., 1988; Palker et al., 1988; Rusche et al., 1988) .
Early excitement about the possibility of creating an effective vaccine based only on intact gp120 or smaller fragments containing the V3 loop region has since abated. Although these constructs can induce a strong immune response toward V3, the antibodies generated, for the most part, neutralize only laboratory-adapted isolates (TCLA) (Mascola et al., 1994; Matthews, 1994) and are usually specific for only a small number of different strains (Palker et al., 1988) . This puzzling phenomenon is most likely due to differential exposure of V3 on different virus strains, and at different stages of the viral entry process. Primary viral isolates, which utilize the CCR5 coreceptor and are responsible for most initial infections, are extremely resistant to neutralization by the vast majority of antibodies, including most directed against the V3 loop. Thus, the V3 loop may be inaccessible in primary isolates, either due to masking by carbohydrate or because of tertiary or quaternary interactions with the gp120 oligomeric complex. As viruses adapt to live in cell culture, or mutate in vivo in the progression toward full-blown AIDS, their V3 regions change in sequence and acquire more positively charged residues (de Jong et al., 1992a; Fouchier et al., 1992) . The viruses then become more amenable to neutralization, presumably because their V3 regions become more accessible for interaction with antibodies, due either to local conformational changes within or around V3 or to destabilization of the gp120 oligomeric assembly.
The gp120 glycoprotein appears to adopt several different conformational states, such as after the cleavage of gp160 to gp120 and gp41 (McCune et al., 1988) , after CD4 binding (Kang et al., 1993; McKeating et al., 1992; Myszka et al., 2000; Sattentau and Moore, 1991; Sattentau et al., 1993; Thali et al., 1993; Xiang et al., 2002) , and after interaction with coreceptor (Chan and Kim, 1998; Freed and Martin, 1995; Wyatt and Sodroski, 1998) . These conformational changes include variation in V3 shape or exposure (Stamatatos and Cheng-Mayer, 1995) , as shown by changes in V3 reactivity with conformation-dependent antibodies. Better understanding of the structural changes that can take place in gp120 is essential to fully explain mechanisms of receptor binding and membrane fusion.
To date, the only available crystal structures for gp120 are for deglycosylated core regions of gp120 from HXB2 and YU2 isolates, where 52 N-and 19 C-terminal, 67 V1/V2, and 32 V3 loop residues (298 -229) have been deleted (Kwong et al., 1998 . While these groundbreaking structures of monomeric gp120 core regions have provided a plethora of extraordinarily valuable structural information, many unanswered questions remain about the range of conformational states that gp120 can adopt. By studying the conformations of V3 that are recognized by neutralizing antibodies, we aim to resolve the issue of how the V3 loop is differentially recognized by antibodies and how alterations in its sequence, conformation, or exposure may affect the biological and virological properties of the virus.
To address these questions, our laboratory and others have carried out various structural studies of peptides with sequences corresponding to V3 loops from different HIV-1 isolates. We have previously determined crystal structures for neutralizing Fabs 50.1 , 59.1 (Ghiara et al., 1994 (Ghiara et al., , 1997 , and 58.2 (Stanfield et al., 1999) in complex with V3 peptides (encompassing residues P303-P320, KRKRIHIGPGRAFYTT) and have shown that two of the antibodies (50.1 and 59.1) recognize one particular V3 conformation, while 58.2 recognizes an alternate V3 conformation that differs mainly at the extreme loop tip encompassing the highly conserved GPGRAF sequence. However, both V3 conformations contain a ␤-strand (residues KRKIHI) followed by a double ␤-turn around residues GPGRAF (Fig. 1) .
A recent crystal structure has been determined for a V3 fusion protein, where V3 was inserted into the coat protein VP1 from the rhinovirus type 14 virus and the structure of the entire virus was determined (Ding et al., 2002) . The insert contained V3 residues IGPGRAFYTTKN, with a three-residue linker (ADT) located at the N-terminus. In the virus crystal structure, a type I turn exists around DTIG, a type II turn around GRAF, and another type I turn around TTKN, but, surprisingly, the GPG region, which is always a ␤-turn in complex with neutralizing Fabs, is in an extended conformation in this viral fusion protein (Fig. 1) . The V3 insert is not involved in any crystal contacts; however, it makes many contacts with the chimeric viral protein, possibly influencing its conformation (Ding et al., 2002) . This modified virus still binds Fabs 59.1 and 58.2, so presumably the V3 insert can adjust its conformation to conform to these two quite different antibody-combining sites.
In addition, NMR studies have been carried out for the neutralizing antibody 0.5␤ in complex with a peptide corresponding to the IIIB isolate sequence (Balbach et al., 2000; Tugarinov et al., 1999 Tugarinov et al., , 2000 Weliky et al., 1999; Zvi et al., 1995 Zvi et al., , 1997 Zvi et al., , 2000 , which forms a hairpin turn when bound to the antibody (Fig. 1) . Another recent NMR study of an MN V3 peptide bound to antibody 447-52D confirms that the peptide again forms a hairpin turn, but with a ␥-turn around residues GPGR (Sharon et al., 2003) (Fig. 1) . A large number of other NMR studies have indicated that V3 peptides are mostly disordered in water solution, with some evidence for transient ␤-turns around the GPGR region (Catasti et al., 1995 (Catasti et al., , 1996 Chandrasekhar et al., 1991; de Lorimier et al., 1994; Dettin et al., 1993 Dettin et al., , 1997 Ghiara et al., 1997; Gupta et al., 1993; Huang et al., 1996 Huang et al., , 1997 Markert et al., 1996; Sarma et al., 1997; Vranken et al., 1996; Vu et al., 1996 Vu et al., , 1999 Zvi et al., 1992) . NMR experiments designed to confer more secondary structure on the peptides have included adding 20% TFE (Catasti et al., 1995 (Catasti et al., , 1996 Chandrasekhar et al., 1991; Vranken et al., 1996; Zvi et al., 1992) , which usually stabilizes an ␣-helical region C-terminal to the GPGR motif ( Fig. 1 ). Other methods that have been used to stabilize V3 loop peptide conformation in solution include peptide cyclization (Cabezas et al., 2000; Chandrasekhar et al., 1991; Gupta et al., 1993; Huisman et al., 2000; Tolman et al., 1993; Vranken et al., 1995 Vranken et al., , 1996 Vranken et al., , 2001 , addition of the conformationally restricted residue aminoisobutyric acid (Cabezas et al., 2000; Ghiara et al., 1997) , glycosylation of the peptide (Huang et al., , 1997 Markert et al., 1996) , attachment to resin beads (Jelinek et al., 1997b) , attachment to a bacteriophage viral coat protein (Jelinek et al., 1997a) , and attachment to other carrier proteins, such as BPTI (Wu et al., 2000) , and MUC1 . These stabilized peptides are more ordered, with increased turn propensity in the GPGRAF region. Interestingly, attachment of V3 peptides to the filamentous bacteriophage fd viral coat protein pVIII (Jelinek et al., 1997a ) stabilizes a peptide conformation with a double turn similar to that seen in the the crystal structure of the Fab 59.1-peptide complex.
Antibody 83.1 is one of a group of five antibodies isolated from mice by Repligen Corp. in early HIV-1 neutralization studies (White-Scharf et al., 1993) . These antibodies were all raised against a 40-mer disulfide-linked peptide containing the V3 sequence from the MN viral isolate. While over 85,000 different hybridomas were produced in these experiments, only 5 were chosen for further study based on their superior neutralization properties. Some monoclonal antibodies are very isolate-specific, while others neutralize a broader range of viral strains, with two of them (83.1 and 58.2) even capable of neutralizing M-tropic isolates and field isolates passaged only one to two times (White-Scharf et al., 1993) .
Results and discussion
Despite good quality electron density maps (Fig. 2) , repeated cycles of refinement and manual rebuilding resulted in slightly higher R cryst and R free values (28.8%, 32.6%) than typically seen for other structures determined at 2.6 Å resolution (R free Х 25-29%) (Kleywegt and Jones, 2002) . Tests for twinning (Yeates, 1997) were negative. These slightly higher R-values appear to reflect a noncrystallographic translation (x,y,z ϭ 0,0,0.45) between the two Fab molecules in the asymmetric unit. A noncrystallographic translation of this type will result in reflections where the index (0.45*l) is close to an integer value to be systematically strong, whereas reflections where (0.45*l) is close to one-half integer are systematically weak. For example, the h,k,9 class of reflections should be strong, while Note. Where l*0.45 is approximately integer, the average reflection intensity is higher than average. Where l*0.45 is approximately 1/2*integer, the average intensities are lower than average. Fig. 1 . Comparison of V3 peptide conformations determined by X-ray crystallography and NMR. Peptides bound to 50.1 (a) and 59.1 (b) (Ghiara et al., 1994 (Ghiara et al., , 1997 are very similar for the five residues in common (HIGPG) with a type II turn around GPGR. (c) The V3 insert from a V3-rhinovirus chimera (Ding et al., 2002) . This structure was determined for the unliganded virus with no bound Fab. The V3 conformation has no significant structural homology with any of the others determined to date, yet the chimeric virus will bind anti-V3 neutralizing antibodies. (d) The peptide bound to Fab 58.2 (Stanfield et al., 1999 ) is similar to (a) and (b) for N-terminal residues RIHI and C-terminal residues AFY; however, the GPGR region has a type I turn conformation. (e) An NMR structure determined for a V3 peptide in solution with 20% TFE (Vranken et al., 1995) . The N-terminal region of the peptide is highly disordered, so has not been included in this figure. This structure shows a distorted type I turn around GPGR. (f) The NMR structure of an MN peptide bound to Fab 447-52D (Sharon et al., 2003) is similar to (a) and (b) for the N-terminal extended region KRIHI, but with a ␥-turn around GPGR. (g) The NMR structure of a IIIB peptide bound to Fab 0.5␤ (Balbach et al., 2000; Tugarinov et al., 1999 Tugarinov et al., , 2000 Weliky et al., 1999; Zvi et al., 1995a Zvi et al., , 1995b Zvi et al., , 1997 has an unclassified turn around residues GPGR, and a QR insert prior to GPGR, characteristic of IIIB-like viruses. Fig. 2 . Stereoview of electron density for the V3 peptide bound to 83.1. The peptide electron density is from a A -weighted, 2F o -F c map contoured at 1.0 with the final peptide coordinates superimposed. This figure was calculated with BobScript (Esnouf, 1999) and rendered with Raster3D (Merritt and Bacon, 1997).
the h,k,10 class of reflections should be weak (Table 1) . This atypical intensity distribution is reflected in the value for mean ͉E**2 Ϫ 1͉, which is expected to be 0.74 for noncentrosymmetric space groups with a random intensity distribution (Karle et al., 1965) , but is higher (0.80) than normal for the Fab 83.1 data. Thus, the larger percentage of systematically weak data results in slightly higher than expected R cryst and R free values. If reflections with F Ͻ 2.0F are removed from the calculation; R cryst and R free for the final model are 24.9 and 28.7%, respectively (4514 or 14.8% of the reflections would be rejected, if these criteria were used).
One residue (Val L51 ) from each Fab molecule is located in the disallowed region of the Ramachandran plot. This residue is the central residue in the highly conserved, three residue ␥-turn which is the primary canonical structure seen for L2 complementarity determining region (CDR) loops (Al-Lazikani et al., 1997) . Residues Ser L27e and Ser
L28
, which are in a mobile region at the tip of L1, are in the generously allowed region, as is Ser H15 , which is correctly positioned as judged from the strong and clear electron density at this position. Ser
H82b
, from the second molecule in the asymmetric unit, is also in the generously allowed region and has clear electron density. Final statistics for the refined structure are listed in Table 2 . The two Fab molecules in the asymmetric unit both have elbow angles of 133° (  Fig. 3) .
With the exception of L1, the CDR loops all fall into their expected canonical classes (Al-Lazikani et al., 1997; Chothia and Lesk, 1987; Martin and Thornton, 1996) , with L2, L3, H1, and H2 belonging to Chothia canonical classes 1, 1, 1, and 1, respectively. The L1 CDR has a five amino acid insertion after residue L27, and, in both Fabs in the asymmetric unit, the tip of this loop bends away from the antigen binding site in an unusual manner. Electron density is weak for the tip of the loop (residues His L27d , Ser L27e , Ser L28 , and Gly L29 ), and, as a result, Ser L27e and Ser L28 have torsion angles in the generously allowed region of the Ramachandran plot. A comparison of this loop in 83.1 with several CDR L1 loops of the same size (Fig. 4a) shows the tip of the loop moves about 9 Å away from its corresponding position in these other Fabs, due to crystal packing, as the loop would otherwise clash with residues Pro H41 and Gly H42 from a symmetry-related molecule (n.b. this same crystal contact is present for both molecules in the asymmetric unit) (Fig. 4b) . Residues H128 -H135 for both molecules are disordered, as seen in other Fab structures, and have been assigned occupancies of 0.0 in the coordinate file.
CDR H3 has a "kinked" or "bulged" base (Al-Lazikani et al., 1997; Morea et al., 1998; Shirai et al., 1996) that would not have been predicted from its sequence. Fab 83.1 has an Ala at H93, an Ile at H94, and an Asp at H101 (Table 3) . Normally, if Asp H101 is able to form a salt bridge with a charged residue at H94 (Arg or Lys), then the side chain of Trp H103 will hydrogen bond to the main-chain carbonyl 
e R free is the same as R cryst but for 5% of the data excluded from the refinement. Fig. 5 . Stereoview of H3 loop conformations from Fabs 83.1 (top), B02C11 (middle), and 26-10 (bottom). Each of these H3 loops has a "bulged" or "kinked" torso, rather than the predicted extended torso, with AspH101 unexpectedly not interacting with the indole nitrogen from Trp H103.
oxygen of the residue three positions upstream, resulting in a kinked base. 83.1 has no charged side chain at position H94 to interact with Asp H101 , and, surprisingly, the only interaction made by the Asp H101 side chain is a single hydrogen bond to a water molecule. Asp H101 is close (ϳ6 Å) to the positively charged N-terminus of the peptide ligand (Lys P305 , Arg P306 ), but makes no direct interactions with the peptide in the crystal structure. At least two other Fabs have kinked H3 bases not predicted by their sequence, Fab 26-10 (1IGJ) (Jeffrey et al., 1993) (Fig. 5) . In the 26-10 structure, Asp H101 is stabilized by a hydrogen bond to Tyr H27 OH, and in the B02C11 structure, Asp H101 makes two hydrogen bonds to the main-chain amide nitrogens of Asp H96 and Ala H99 . Clear electron density is present for 10 residues of the 16-mer bound V3 peptide, allowing the structure of residues P305-P316 (KRIHIGPGRA) to be interpreted from the maps (Fig. 2) . Additional weak electron density is seen at either end of this 10-mer peptide, but has not been modeled due to difficulty in its interpretation. Residues at the Nterminus (KRIHIG) are in an extended conformation, followed by a type I turn around residues GPGR and the start of a type II turn around GRA. The peptide forms a double turn, very similar in shape to that seen in both the Fab 59.1-peptide (Ghiara et al., 1994 (Ghiara et al., , 1997 and the Fab 50.1-peptide structures (Fig. 6) . Differences in main-chain torsion angles arise compared to the 59.1 peptide, due to different locations of the carbonyl oxygens of P309, P313, and P315 in the 83.1 or 59.1 structures; nevertheless, the overall shape of the peptide remains the same. Although the medium resolution data of these structures (2.8 and 3.0 Å for 59.1, and 2.57 Å for 83.1) can sometimes make the exact positioning of carbonyl oxygens problematic, repeated inspections of the 83.1 and 59.1 electron density maps indicate that the carbonyl oxygens are correctly positioned. The 83.1 peptide also differs slightly from the 50.1 and 59.1 peptides in the relative disposition of the extended region Fig. 6 . Comparison of the V3 peptide conformations from complexes with Fabs 50.1 (pink), 59.1 (gray), 83.1 (green), and 58.2 (blue). The peptides have all been superimposed onto the V3 loop peptide from 50.1, and their overlapped C␣ traces are shown at the bottom right. The 83.1 peptide has a very similar shape to the 50.1 and 59.1 peptides for both its extended region (KRIHIG) and its crown (GPGRA); however, a slight difference is seen in the disposition of these two segments. The superposition for 83.1 was carried out using the crown residues. Fig. 7 . The antibody combining site of Fab 83.1. Stereoview of the Fab binding site and its interactions with the V3 peptide. Contacting residues were identified with Contacsym (Sheriff et al., 1987a) . The peptide residues are labeled in black; the light chain residues are labeled in red, and the heavy chain residues are labeled in blue. The molecular surface for the Fab was calculated with GRASP (Nicholls et al., 1991) and is colored according to the electrostatic potential (blue ϭ positive, red ϭ negative, surface potential from Ϫ15 to 15 kT). Table 3 Sequences of the anti-V3 Fabs 83.1, 59.1 (Ghiara et al., 1994 (Ghiara et al., , 1997 , 50.1 , and 58.2 (Stanfield et al., 1999) 
PSLKSRISFTRDTSKNQFYLKLNSVTTEDTATYYCAIDDF------------DIWGAGTTVTVSS

PSIKSRSTISRDTSLNKFFIQLISVTNEDTAMYYCSRKNHMYETYF------DVWGQGTTVTVSS
PSLKSRLKISKDTSNNQVFLKITSVDTADTATYYCVQEGY------------IYWGQGTSVTVSS
PSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCAREEAMPYGNQAYYYAMDCWGQGTTVTVSS CDR 3
(P305-P312) versus the double turn region (P312-P316), by an angle of about 60° (Fig. 6) . The peptide makes contact with both the light and the heavy chains from the Fab, with 110 (107) total contacts for molecule 1 (molecule 2) (Fig. 7) . Of these contacts, 7 (8) are hydrogen bonds, with no charge-charge interactions (Table  4) . Six (7) hydrogen bonds are to peptide main-chain atoms, with 1 (1) bond to the Arg P315 side chain. The H3 CDR makes the most contacts (39%, 37%), followed by H1 (20%, 15%), L1 (10%, 12%), L2 (4%, 4%), L3 (9.1%, 14.0%), H2 (7%, 6%), light-chain framework residues (10%), and heavy-chain framework residues (1%). The peptide buries 478 (479) Å 2 , while the Fab buries 490 (549) Å 2 of molecular surface, with about 50 (59)% of the total from the heavy chain.
The 83.1-peptide structure is the fourth crystal structure determined for a neutralizing antibody-V3 peptide complex. Analysis of the conformations of the four peptides reveals that three of the peptides share very similar conformations (Fig. 6) , while that of the fourth (58.2) differs around the residues at the tip of V3 (GPGR). The four antipeptide antibodies (83.1, 50.1, 59.1, 58 .2) were all generated during the same set of experiments from related mice, and the peptides used for immunization and for cocrystallization all correspond to the MN viral isolate sequence. However, the antibodies themselves do not have strong sequence (Table 3) or structural homology (Fig. 8) , and in fact, have CDR loops of various size, shape, and sequence composition. Thus, the similarity among conformation of the three peptides bound to 50.1, 59.1, and 83.1 is not because the Fabs themselves are highly similar. In fact, the peptides, although adopting the same shapes, bind in different orientations and locations in the antibody-combining site (Fig. 8) . Because the antibodies were chosen for their ability to neutralize, and, hence, to bind to intact virus, these peptide conformations should reflect highly populated or energetically preferred conformations of the V3 loop on the intact virus. If V3 were totally disordered and had no stable structure, it is unlikely that three different neutralizing antibodies would recognize such similar peptide conformations. Thus, the V3 loop structures that we have identified would appear to represent a recurring and highly populated conformer on the intact virus, suggesting that the different peptide conformation observed when bound to Fab 58.2 may also be conformationally accessible on the intact virus.
These X-ray crystallographic "snapshots" of V3 peptides in complex with neutralizing antibodies help define the range of conformations that V3 can adopt. As most studies suggest that V3 interacts with coreceptors CCR5 and CXCR4 during viral cell entry, this structural information may be useful in the design of V3-based fusion inhibitors. Ultimately, a better understanding of the quaternary structure of intact gp120/gp41 oligomers as they exist on the viral surface, and of the role of V3 in this complex protein assembly, is essential for truly understanding how HIV-1 carries out its receptor binding and viral fusion activities.
Materials and methods
Fab purification and crystallization
MAb 83.1 (IgG1,) was generated by immunization of ASW mice with cyclic peptide RP70 (INC*TRPN-YNKRKRIHIGPGRAFYTTKNIIGTIRQAHC*NIS with a disulfide bond between the two C* residues) corresponding to the MN sequence (White-Scharf et al., 1993) . The antibody was produced in ascites fluid of BALB/c mice and purified with an immobilized protein A column. Fab fragments were produced from immunoglobulin by cleavage with 3% pepsin for 2 h at 37°C, reduction with 15 mM cysteine for 3 h at 37°C, followed by purification on a protein A and then a protein G column (Smith, 1993) . Fab was concentrated to 15.0 mg/ml for crystallization studies.
Fab was mixed with linear 16-mer peptide MP1 (CKRI-HIGPGRAFYTTC) in a 6:1 (peptide:Fab) molar ratio. Crystals were grown using the sitting-drop vapor diffusion method with a reservoir solution (1 ml) of 1.6 M Na/K phosphate, 5% isopropanol, pH 6.0. One microliter of Fab/ peptide complex was mixed with an equal volume of the reservoir solution. The crystals grow as clusters of thin plates. Crystals were usually observed after 3 days; however, the crystal used for data collection grew over a 2-week period, was slightly thicker than typically seen, and grew singly with no satellite crystals attached.
Data collection
As the 83.1-peptide crystals suffer from significant radiation-induced decay, even when cryocooled to liquid nitrogen temperatures, efforts were taken to collect the data as rapidly as possible. Data were collected from a single crystal at the Advanced Photon Source, beamline 19-ID, at 100K, using a wavelength of 1.033 Å and a step size of 0.5°w ith a CCD detector. The crystals were cryoprotected by a quick plunge into a solution containing 25% glycerol, 1.6 M Na/K phosphate, 5% isopropanol, pH 6.0. The data were reduced in monoclinic space group P2 1 with unit cell dimensions a ϭ 60.5 Å, b ϭ 122.6 Å, c ϭ 69.5 Å, and ␤ ϭ 108.5°and a refined mosaicity of 0.8°. Data were indexed, integrated, and scaled using HKL2000 (Otwinowski and Minor, 1997 ) using all observations greater than Ϫ3.0. Data collection statistics are outlined in Table 2 .
Structure determination
The Matthews coefficient (V m ) (Matthews, 1985) was estimated as 2.6 Å 3 /D based on two Fab molecules in the asymmetric unit (53% solvent). The native Patterson map showed an unexpected peak at u, v, w ϭ 0.0, 0.0, 0.45 with a peak height of 37 (the origin peak height was 150) indicative of a noncrystallographic translation between the two Fab molecules in the asymmetric unit of approximately 0, 0, 1/2. Rotation functions were carried out using the Crowther fast rotation function (Crowther and Blow, 1967) , as implemented in MERLOT (Fitzgerald, 1988) , against our database of 125 intact Fab models. Strong rotation function solutions were found for models with elbow angles of approximately 135°, with Fab 59.1 (1ACY) (Ghiara et al., 1994) providing the best solution. A model was then constructed from the constant region (C H 1, C L ) of Fab 58.2 (from unpublished coordinates refined to 1.6 Å resolution, and with the appropriate sequence for an IgG1, ) (Stanfield et al., 1999) , the V L domain of an anti-Dansyl antibody (1DLF) (Nakasako et al., 1999 ) (88% sequence identity), and the V H domain of HyHEL-63 (1DQQ) (Li et al., 2000) (84% sequence identity) assembled with an elbow angle of 135°by superposition over the corresponding domains of Fab 59.1 (1ACY). The EPMR (Kissinger et al., 1999) program was then used to correctly position this model in the cell, followed by positional refinement using four individual domains (the variable and constant regions from each molecule in the asymmetric unit). EPMR located the first Fab molecule in the asymmetric unit with a correlation coefficient of 28.7% and an R-value of 55.8%, and, subsequently, the second Fab molecule (holding the first molecule fixed) with a correlation coefficient of 50.8% and an R-value of 46.8%.
Model building and refinement
The hybrid model was mutated to the correct sequence for 83.1, rebuilt using TOM/FRODO (Jones, 1982) , and refined with CNS version 1.1 (Brünger et al., 1998) with an overall, anisotropic B-value correction and bulk solvent correction. All refinement and model building were carried out using all measured data (F Ͼ 0.0F), with tight NCS restraints early on in the refinement, which were released gradually toward the end of refinement. Electron density maps for model building included A -weighted (Read, 1986 ) 2F 0 Ϫ F c , F 0 Ϫ F c and composite annealed omit 2F 0 Ϫ F c maps, as well as solvent flippped/NCS-averaged 2F 0 Ϫ F c maps, all calculated with CNS (Brünger et al., 1998 ). An R free test set consisting of 5% of the reflections was maintained throughout the refinement.
Structure analysis
The Fab molecules are numbered according to the Kabat convention (Kabat et al., 1991) with light and heavy chains labeled "L" and "H." The peptide is labeled "P" and is numbered according to the HXB2 isolate sequence (305) (306) (307) (308) (309) (312) (313) (314) (315) (316) . Buried molecular surface areas were calculated with the program MS (Connolly, 1993 ) with a 1.7 Å probe radius and standard van der Waals radii (Gelin and Karplus, 1979) . Hydrogen bonds were evaluated using the program HBPLUS (McDonald and Thornton, 1994) and van der Waals contacts were assigned with the program Contacsym (Sheriff et al., 1987a (Sheriff et al., , 1987b .
